annual EBITDA:
$486.30M-$4.12B(-89.44%)Summary
- As of today (April 25, 2025), VRTX annual EBITDA is $486.30 million, with the most recent change of -$4.12 billion (-89.44%) on December 31, 2024.
- During the last 3 years, VRTX annual EBITDA has fallen by -$2.43 billion (-83.33%).
- VRTX annual EBITDA is now -89.44% below its all-time high of $4.61 billion, reached on December 31, 2023.
Performance
VRTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
$1.19B-$99.00M(-7.71%)Summary
- As of today (April 25, 2025), VRTX quarterly EBITDA is $1.19 billion, with the most recent change of -$99.00 million (-7.71%) on December 31, 2024.
- Over the past year, VRTX quarterly EBITDA has dropped by -$31.40 million (-2.58%).
- VRTX quarterly EBITDA is now -11.71% below its all-time high of $1.34 billion, reached on March 31, 2024.
Performance
VRTX quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$486.30M-$31.40M(-6.07%)Summary
- As of today (April 25, 2025), VRTX TTM EBITDA is $486.30 million, with the most recent change of -$31.40 million (-6.07%) on December 31, 2024.
- Over the past year, VRTX TTM EBITDA has dropped by -$4.12 billion (-89.44%).
- VRTX TTM EBITDA is now -90.29% below its all-time high of $5.01 billion, reached on March 31, 2024.
Performance
VRTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
VRTX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -89.4% | -2.6% | -89.4% |
| 3 y3 years | -83.3% | -3.3% | -88.5% |
| 5 y5 years | -68.8% | -3.3% | -88.5% |
VRTX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -89.4% | at low | -11.7% | +135.6% | -90.3% | +4.6% |
| 5 y | 5-year | -89.4% | at low | -11.7% | +135.6% | -90.3% | +4.6% |
| alltime | all time | -89.4% | +169.0% | -11.7% | +135.6% | -90.3% | +168.8% |
Vertex Pharmaceuticals Incorporated EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | $486.30M(-89.4%) | $1.19B(-7.7%) | $486.30M(-6.1%) |
| Sep 2024 | - | $1.28B(-138.6%) | $517.70M(+11.3%) |
| Jun 2024 | - | -$3.33B(-347.8%) | $465.10M(-90.7%) |
| Mar 2024 | - | $1.34B(+10.3%) | $5.01B(+8.7%) |
| Dec 2023 | $4.61B(+3.8%) | $1.22B(-1.2%) | $4.61B(+2.0%) |
| Sep 2023 | - | $1.23B(+1.5%) | $4.51B(+0.1%) |
| Jun 2023 | - | $1.21B(+28.9%) | $4.51B(+3.2%) |
| Mar 2023 | - | $941.70M(-16.4%) | $4.37B(-1.4%) |
| Dec 2022 | $4.44B(+52.0%) | $1.13B(-8.2%) | $4.44B(+4.9%) |
| Sep 2022 | - | $1.23B(+14.0%) | $4.23B(+2.4%) |
| Jun 2022 | - | $1.08B(+7.0%) | $4.13B(+35.1%) |
| Mar 2022 | - | $1.01B(+9.3%) | $3.06B(+4.8%) |
| Dec 2021 | $2.92B(-11.2%) | $919.80M(-18.6%) | $2.92B(-0.5%) |
| Sep 2021 | - | $1.13B(>+9900.0%) | $2.93B(+13.3%) |
| Jun 2021 | - | $2.60M(-99.7%) | $2.59B(-25.0%) |
| Mar 2021 | - | $865.40M(-7.4%) | $3.45B(+5.1%) |
| Dec 2020 | $3.28B(+110.5%) | $934.40M(+18.8%) | $3.28B(+7.1%) |
| Sep 2020 | - | $786.37M(-9.1%) | $3.07B(+28.2%) |
| Jun 2020 | - | $865.34M(+23.9%) | $2.39B(+26.1%) |
| Mar 2020 | - | $698.49M(-2.6%) | $1.90B(+21.6%) |
| Dec 2019 | $1.56B(+109.4%) | $717.39M(+545.9%) | $1.56B(+70.9%) |
| Sep 2019 | - | $111.06M(-70.0%) | $912.97M(-6.5%) |
| Jun 2019 | - | $369.67M(+2.1%) | $976.30M(+13.6%) |
| Mar 2019 | - | $362.17M(+416.9%) | $859.43M(+15.3%) |
| Dec 2018 | $745.13M(+547.9%) | $70.07M(-59.8%) | $745.13M(-10.0%) |
| Sep 2018 | - | $174.39M(-31.0%) | $828.23M(+212.0%) |
| Jun 2018 | - | $252.81M(+2.0%) | $265.47M(+241.5%) |
| Mar 2018 | - | $247.87M(+61.8%) | $77.73M(-32.4%) |
| Dec 2017 | $115.01M(+52.4%) | $153.17M(-139.4%) | $115.01M(+537.8%) |
| Sep 2017 | - | -$388.37M(-696.9%) | $18.03M(-95.5%) |
| Jun 2017 | - | $65.06M(-77.2%) | $402.08M(+13.5%) |
| Mar 2017 | - | $285.15M(+407.4%) | $354.12M(+369.3%) |
| Dec 2016 | $75.46M(-118.3%) | $56.20M(-1399.3%) | $75.46M(-470.3%) |
| Sep 2016 | - | -$4.33M(-125.3%) | -$20.38M(-71.4%) |
| Jun 2016 | - | $17.10M(+163.2%) | -$71.24M(-70.8%) |
| Mar 2016 | - | $6.50M(-116.4%) | -$244.02M(-40.7%) |
| Dec 2015 | -$411.25M(-31.3%) | -$39.65M(-28.2%) | -$411.25M(-19.8%) |
| Sep 2015 | - | -$55.18M(-64.6%) | -$512.68M(-12.6%) |
| Jun 2015 | - | -$155.69M(-3.1%) | -$586.73M(+4.8%) |
| Mar 2015 | - | -$160.74M(+13.9%) | -$559.69M(-6.5%) |
| Dec 2014 | -$598.75M(+7.9%) | -$141.08M(+9.2%) | -$598.75M(+34.0%) |
| Sep 2014 | - | -$129.23M(+0.5%) | -$446.79M(+4.7%) |
| Jun 2014 | - | -$128.64M(-35.6%) | -$426.88M(+23.9%) |
| Mar 2014 | - | -$199.80M(-1936.4%) | -$344.64M(-39.9%) |
| Dec 2013 | -$554.75M(-750.9%) | $10.88M(-110.0%) | -$573.63M(-5.4%) |
| Sep 2013 | - | -$109.32M(+135.6%) | -$606.55M(+24.0%) |
| Jun 2013 | - | -$46.41M(-89.2%) | -$489.02M(+10.1%) |
| Mar 2013 | - | -$428.78M(+1844.7%) | -$444.13M(-621.1%) |
| Dec 2012 | $85.23M(-36.0%) | -$22.05M(-368.3%) | $85.23M(-74.9%) |
| Sep 2012 | - | $8.22M(-643.9%) | $339.46M(-37.9%) |
| Jun 2012 | - | -$1.51M(-101.5%) | $546.66M(+40.5%) |
| Mar 2012 | - | $100.57M(-56.7%) | $388.97M(+192.1%) |
| Dec 2011 | $133.17M(-118.9%) | $232.18M(+7.8%) | $133.17M(-150.5%) |
| Sep 2011 | - | $215.42M(-235.3%) | -$263.52M(-61.1%) |
| Jun 2011 | - | -$159.20M(+2.6%) | -$677.18M(-4.1%) |
| Mar 2011 | - | -$155.24M(-5.6%) | -$706.40M(+0.5%) |
| Dec 2010 | -$704.89M(+17.7%) | -$164.50M(-17.0%) | -$703.08M(-0.1%) |
| Sep 2010 | - | -$198.25M(+5.2%) | -$703.96M(+8.9%) |
| Jun 2010 | - | -$188.41M(+24.0%) | -$646.36M(+6.6%) |
| Mar 2010 | - | -$151.92M(-8.1%) | -$606.26M(+1.2%) |
| Dec 2009 | -$598.88M(+40.5%) | -$165.39M(+17.6%) | -$598.88M(+6.0%) |
| Sep 2009 | - | -$140.64M(-5.2%) | -$565.14M(+3.5%) |
| Jun 2009 | - | -$148.31M(+2.6%) | -$546.29M(+13.8%) |
| Mar 2009 | - | -$144.53M(+9.8%) | -$480.11M(+12.7%) |
| Dec 2008 | -$426.19M(+10.6%) | -$131.65M(+8.1%) | -$426.19M(+12.6%) |
| Sep 2008 | - | -$121.79M(+48.3%) | -$378.56M(+4.3%) |
| Jun 2008 | - | -$82.14M(-9.3%) | -$362.85M(-9.0%) |
| Mar 2008 | - | -$90.61M(+7.8%) | -$398.57M(+3.5%) |
| Dec 2007 | -$385.21M | -$84.02M(-20.8%) | -$385.21M(+17.4%) |
| Sep 2007 | - | -$106.08M(-10.0%) | -$328.23M(+18.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2007 | - | -$117.86M(+52.6%) | -$276.93M(+19.9%) |
| Mar 2007 | - | -$77.25M(+185.8%) | -$231.03M(+15.8%) |
| Dec 2006 | -$199.52M(+74.3%) | -$27.03M(-50.7%) | -$199.52M(+7.5%) |
| Sep 2006 | - | -$54.78M(-23.9%) | -$185.59M(+12.7%) |
| Jun 2006 | - | -$71.97M(+57.3%) | -$164.70M(+30.2%) |
| Mar 2006 | - | -$45.74M(+249.0%) | -$126.54M(+10.6%) |
| Dec 2005 | -$114.45M(+6.4%) | -$13.11M(-61.3%) | -$114.45M(-5.7%) |
| Sep 2005 | - | -$33.89M(+0.2%) | -$121.40M(+6.2%) |
| Jun 2005 | - | -$33.81M(+0.5%) | -$114.33M(+0.6%) |
| Mar 2005 | - | -$33.65M(+67.8%) | -$113.63M(+5.6%) |
| Dec 2004 | -$107.59M(-27.9%) | -$20.05M(-25.2%) | -$107.59M(-10.2%) |
| Sep 2004 | - | -$26.82M(-19.0%) | -$119.82M(-10.9%) |
| Jun 2004 | - | -$33.11M(+20.0%) | -$134.43M(-26.5%) |
| Mar 2004 | - | -$27.61M(-14.5%) | -$182.87M(+42.0%) |
| Dec 2003 | -$149.26M(+21.3%) | -$32.28M(-22.1%) | -$128.81M(-15.1%) |
| Sep 2003 | - | -$41.43M(-49.2%) | -$151.77M(+8.7%) |
| Jun 2003 | - | -$81.55M(-408.2%) | -$139.62M(+84.1%) |
| Mar 2003 | - | $26.45M(-147.9%) | -$75.82M(-38.4%) |
| Dec 2002 | -$123.05M(+26.7%) | -$55.25M(+88.7%) | -$123.05M(+0.7%) |
| Sep 2002 | - | -$29.28M(+65.0%) | -$122.20M(+14.6%) |
| Jun 2002 | - | -$17.75M(-14.6%) | -$106.66M(+3.2%) |
| Mar 2002 | - | -$20.78M(-61.8%) | -$103.31M(+8.3%) |
| Dec 2001 | -$97.14M(+294.0%) | -$54.39M(+295.7%) | -$95.40M(+99.7%) |
| Sep 2001 | - | -$13.74M(-4.5%) | -$47.77M(+1.9%) |
| Jun 2001 | - | -$14.39M(+11.8%) | -$46.89M(+123.9%) |
| Mar 2001 | - | -$12.87M(+90.2%) | -$20.94M(-12.8%) |
| Dec 2000 | -$24.65M(-44.4%) | -$6.77M(-47.4%) | -$24.01M(+51.5%) |
| Sep 2000 | - | -$12.86M(-211.2%) | -$15.85M(-9.9%) |
| Jun 2000 | - | $11.56M(-172.5%) | -$17.59M(-56.9%) |
| Mar 2000 | - | -$15.95M(-1242.3%) | -$40.85M(-7.4%) |
| Dec 1999 | -$44.30M(+2.5%) | $1.40M(-109.6%) | -$44.11M(-38.5%) |
| Sep 1999 | - | -$14.60M(+24.8%) | -$71.70M(+23.4%) |
| Jun 1999 | - | -$11.70M(-39.0%) | -$58.10M(+5.8%) |
| Mar 1999 | - | -$19.20M(-26.7%) | -$54.90M(+16.6%) |
| Dec 1998 | -$43.20M(+176.9%) | -$26.20M(+2520.0%) | -$47.10M(+78.4%) |
| Sep 1998 | - | -$1.00M(-88.2%) | -$26.40M(-12.3%) |
| Jun 1998 | - | -$8.50M(-25.4%) | -$30.10M(+36.8%) |
| Mar 1998 | - | -$11.40M(+107.3%) | -$22.00M(+42.9%) |
| Dec 1997 | -$15.60M(-57.0%) | -$5.50M(+17.0%) | -$15.40M(-36.9%) |
| Sep 1997 | - | -$4.70M(+1075.0%) | -$24.40M(-7.2%) |
| Jun 1997 | - | -$400.00K(-91.7%) | -$26.30M(-21.0%) |
| Mar 1997 | - | -$4.80M(-66.9%) | -$33.30M(-8.3%) |
| Dec 1996 | -$36.30M(+59.2%) | -$14.50M(+119.7%) | -$36.30M(+57.1%) |
| Sep 1996 | - | -$6.60M(-10.8%) | -$23.10M(-1.7%) |
| Jun 1996 | - | -$7.40M(-5.1%) | -$23.50M(-8.6%) |
| Mar 1996 | - | -$7.80M(+500.0%) | -$25.70M(+12.7%) |
| Dec 1995 | -$22.80M(+32.6%) | -$1.30M(-81.4%) | -$22.80M(-21.1%) |
| Sep 1995 | - | -$7.00M(-27.1%) | -$28.90M(+16.1%) |
| Jun 1995 | - | -$9.60M(+95.9%) | -$24.90M(+25.8%) |
| Mar 1995 | - | -$4.90M(-33.8%) | -$19.80M(+15.1%) |
| Dec 1994 | -$17.20M(-437.3%) | -$7.40M(+146.7%) | -$17.20M(>+9900.0%) |
| Sep 1994 | - | -$3.00M(-33.3%) | -$100.00K(-111.1%) |
| Jun 1994 | - | -$4.50M(+95.7%) | $900.00K(-83.6%) |
| Mar 1994 | - | -$2.30M(-123.7%) | $5.50M(+7.8%) |
| Dec 1993 | $5.10M(-170.8%) | $9.70M(-585.0%) | $5.10M(-175.0%) |
| Sep 1993 | - | -$2.00M(-2100.0%) | -$6.80M(+1.5%) |
| Jun 1993 | - | $100.00K(-103.7%) | -$6.70M(-19.3%) |
| Mar 1993 | - | -$2.70M(+22.7%) | -$8.30M(+16.9%) |
| Dec 1992 | -$7.20M(+89.5%) | -$2.20M(+15.8%) | -$7.10M(+16.4%) |
| Sep 1992 | - | -$1.90M(+26.7%) | -$6.10M(+17.3%) |
| Jun 1992 | - | -$1.50M(0.0%) | -$5.20M(+15.6%) |
| Mar 1992 | - | -$1.50M(+25.0%) | -$4.50M(+104.5%) |
| Dec 1991 | -$3.80M(-7.3%) | -$1.20M(+20.0%) | -$2.20M(-67.6%) |
| Sep 1991 | - | -$1.00M(+25.0%) | -$6.80M(+30.8%) |
| Jun 1991 | - | -$800.00K(-200.0%) | -$5.20M(+36.8%) |
| Mar 1991 | - | $800.00K(-113.8%) | -$3.80M(-7.3%) |
| Dec 1990 | -$4.10M | -$5.80M(-1066.7%) | -$4.10M(-341.2%) |
| Sep 1990 | - | $600.00K(0.0%) | $1.70M(+54.5%) |
| Jun 1990 | - | $600.00K(+20.0%) | $1.10M(+120.0%) |
| Mar 1990 | - | $500.00K | $500.00K |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual EBITDA?
- What is the all time high annual EBITDA for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual EBITDA year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly EBITDA?
- What is the all time high quarterly EBITDA for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly EBITDA year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM EBITDA?
- What is the all time high TTM EBITDA for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM EBITDA year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual EBITDA?
The current annual EBITDA of VRTX is $486.30M
What is the all time high annual EBITDA for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual EBITDA is $4.61B
What is Vertex Pharmaceuticals Incorporated annual EBITDA year-on-year change?
Over the past year, VRTX annual EBITDA has changed by -$4.12B (-89.44%)
What is Vertex Pharmaceuticals Incorporated quarterly EBITDA?
The current quarterly EBITDA of VRTX is $1.19B
What is the all time high quarterly EBITDA for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly EBITDA is $1.34B
What is Vertex Pharmaceuticals Incorporated quarterly EBITDA year-on-year change?
Over the past year, VRTX quarterly EBITDA has changed by -$31.40M (-2.58%)
What is Vertex Pharmaceuticals Incorporated TTM EBITDA?
The current TTM EBITDA of VRTX is $486.30M
What is the all time high TTM EBITDA for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM EBITDA is $5.01B
What is Vertex Pharmaceuticals Incorporated TTM EBITDA year-on-year change?
Over the past year, VRTX TTM EBITDA has changed by -$4.12B (-89.44%)